Correct usage and recommended dosage of mitapivat-Pyrukynd

Mitapivat (mitapivat)-Pyrukynd is an oral medication primarily used to treat hereditary spherocytosis caused by pyruvate kinase deficiency (PK deficiency). This drug reduces hemolysis and improves anemia symptoms by promoting the normal function of red blood cell metabolism. Correct usage and recommended dosage of Metapival are critical to ensure its therapeutic effectiveness.

Metapival should be taken as directed by your doctor and swallow the tablet whole. Patients should not break, crush, chew or dissolve the tablets as this may affect the effectiveness of the medicine. Metapival can be taken with food or on an empty stomach, but care should be taken not to interact with other drugs or foods when taking the drug to avoid affecting drug absorption. Patients should maintain regular communication with their doctor while taking the medication so that necessary adjustments can be made based on the treatment effect.

The dose of mitava should be adjusted based on the patient's condition, hemoglobin level, and transfusion requirements. Typically, doctors will assess a patient's response early in treatment and decide whether a dose increase is needed.

1. Starting dose: The recommended starting dose of mitava is 5 mg twice daily. This dose is suitable for all initial patients and should be used during the first four weeks after the start of treatment.

2. Dose titration: In order to achieve optimal therapeutic effects, the dose of mitapival usually needs to be adjusted over the next few months based on hemoglobin levels and the patient's blood transfusion requirements. During treatment, the doctor will evaluate the patient's hemoglobin level every four weeks and adjust the dose based on the following criteria:

Weeks 1-4: Initial dose: 5 mg twice daily.

Weeks 5-8 weeks: If the hemoglobin is below the normal range or there is a need for blood transfusion in the past 8 weeks, the dose will be increased to 20 mg twice a day; if the hemoglobin is within the normal range and there is no need for blood transfusion, continue to maintain 5 mg twice a day.

Weeks 9-12: If hemoglobin is still below the normal range or a blood transfusion has been required within the past 8 weeks, the dose is increased to 50 mg twice daily, which is the maximum recommended dose. If hemoglobin is within the normal range and no transfusion is required, maintain the current dose (5 mg or 20 mg twice daily).

3. Treatment termination criteria: If treatment has not been effective after 24 weeks, and the hemoglobin level, hemolysis indicators and blood transfusion requirements have not improved, the doctor may consider stopping the treatment.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd